Dana-Farber researchers find that combined therapy can reduce chance of recurrence in women with small, HER2+ breast tumors

Dana-Farber researchers report women with small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years. …read more

Source:: Cancer